Medicine
Ibrance 100 mg tablet
Ibrance 100 mg tablet is a prescription medicine containing Palbociclib for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Palbociclib
- Brand
- Ibrance
- Strength
- 100 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 3 dose packs
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Store in the original blister pack.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EF01 Palbociclib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 March 2020
- Identifiers
- RxCUI 2284102, 2284104, 2284105 +3DailyMed set ID 89a142d5-7e61-48bf-9e77-e2cd124c4792, fecbdd7d-b729-41b5-9872-231b8fe104ceNDC 63539-486, 0069-0486Application NDA212436
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 dose pack in 1 carton / 7 tablet, film coated in 1 dose pack | 0069-0486-03 | Pfizer Laboratories | 30 March 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Palbociclib
Clinical summary
Palbociclib is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, among other approved uses. MedsAcross supplies Palbociclib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PalbociclibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ibrance prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
- Ibrance: European public assessment report (EPAR) · European Medicines Agency
- Palbociclib Viatris: European public assessment report (EPAR) · European Medicines Agency
Need Ibrance 100 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.